BACKGROUND AND AIM: Genetic alterations in the normal tissues surrounding various cancers have been described, but a comprehensive analysis of this carcinogenic field effect in Barrett's-associated adenocarcinoma of the esophagus disease has not been reported. The aim of this study was to analyze the gene expression profile of a panel of highly selected genes in the normal squamous esophagus epihelium of patients with Barrett's esophagus, patients with Barrett's-associated adenocarcinoma, and a healthy control group to define the existence of a carcinogenic field effect, and to investigate the clinical importance of such a field effect in the management of Barrett's disease. METHODS: Forty-nine histologic normal squamous esophageal epithelia collected from 19 patients with Barrett's esophagus, 20 patients with Barrett's-associated esophageal adenocarcinoma, and a healthy control group of 10 patients were studied. A quantitative real-time reverse transcription-PCR method (TaqMan) was used to measure the expression of a panel of genes with known associations with gastrointestinal carcinogenesis. RESULTS: A widespread carcinogenic field effect was detected for more than 50% of the genes analyzed including Bax, BFT, CDX2, COX2, DAPK, DNMT1, GSTP1, RARalpha, RARgamma, RXRalpha, RXRbeta, SPARC, TSPAN, and VEGF. Based on the expression signature of the normal appearing squamous esophagus, a linear discriminant analysis was able to distinguish between the three groups of patients with an error rate of 0%. CONCLUSION: This study provides the first comprehensive investigation of a carcinogenic field effect in Barrett's esophagus disease. Based on the gene expression signature of the normal esophagus, patients could be correctly characterized according to their pathologic classification by applying a linear discriminant analysis. Our results provide evidence that a molecular classification might have clinical importance for the diagnosis and treatment of patients with Barrett's esophagus disease.
BACKGROUND AND AIM: Genetic alterations in the normal tissues surrounding various cancers have been described, but a comprehensive analysis of this carcinogenic field effect in Barrett's-associated adenocarcinoma of the esophagus disease has not been reported. The aim of this study was to analyze the gene expression profile of a panel of highly selected genes in the normal squamous esophagus epihelium of patients with Barrett's esophagus, patients with Barrett's-associated adenocarcinoma, and a healthy control group to define the existence of a carcinogenic field effect, and to investigate the clinical importance of such a field effect in the management of Barrett's disease. METHODS: Forty-nine histologic normal squamous esophageal epithelia collected from 19 patients with Barrett's esophagus, 20 patients with Barrett's-associated esophageal adenocarcinoma, and a healthy control group of 10 patients were studied. A quantitative real-time reverse transcription-PCR method (TaqMan) was used to measure the expression of a panel of genes with known associations with gastrointestinal carcinogenesis. RESULTS: A widespread carcinogenic field effect was detected for more than 50% of the genes analyzed including Bax, BFT, CDX2, COX2, DAPK, DNMT1, GSTP1, RARalpha, RARgamma, RXRalpha, RXRbeta, SPARC, TSPAN, and VEGF. Based on the expression signature of the normal appearing squamous esophagus, a linear discriminant analysis was able to distinguish between the three groups of patients with an error rate of 0%. CONCLUSION: This study provides the first comprehensive investigation of a carcinogenic field effect in Barrett's esophagus disease. Based on the gene expression signature of the normal esophagus, patients could be correctly characterized according to their pathologic classification by applying a linear discriminant analysis. Our results provide evidence that a molecular classification might have clinical importance for the diagnosis and treatment of patients with Barrett's esophagus disease.
Authors: Doerthe Kuester; Altaf A Dar; Christopher C Moskaluk; Sabine Krueger; Frank Meyer; Roland Hartig; Manfred Stolte; Peter Malfertheiner; Hans Lippert; Albert Roessner; Wael El-Rifai; Regine Schneider-Stock Journal: Neoplasia Date: 2007-03 Impact factor: 5.715
Authors: Angelique Levert-Mignon; Michael J Bourke; Sarah J Lord; Andrew C Taylor; Antony R Wettstein; Melanie Edwards; Natalia K Botelho; Rebecca Sonson; Chatura Jayasekera; Oliver M Fisher; Melissa L Thomas; Finlay Macrae; Damian J Hussey; David I Watson; Reginald V Lord Journal: United European Gastroenterol J Date: 2016-07-07 Impact factor: 4.623
Authors: Qiuyang Zhang; Chunhua Yu; Sui Peng; Hao Xu; Ellen Wright; Xi Zhang; Xiaofang Huo; Edaire Cheng; Thai H Pham; Kiyotaka Asanuma; Kimmo J Hatanpaa; Davood Rezai; David H Wang; Venetia Sarode; Shelby Melton; Robert M Genta; Stuart J Spechler; Rhonda F Souza Journal: Gastroenterology Date: 2013-10-09 Impact factor: 22.682
Authors: Carol Bernstein; Harris Bernstein; Claire M Payne; Katerina Dvorak; Harinder Garewal Journal: Cancer Lett Date: 2007-12-31 Impact factor: 8.679
Authors: Roberto Herrera-Goepfert; Luis F Oñate-Ocaña; José Luis Mosqueda-Vargas; Luis A Herrera; Clementina Castro; Julia Mendoza; Rodrigo González-Barrios Journal: World J Gastroenterol Date: 2016-05-14 Impact factor: 5.742
Authors: Hariharan Subramanian; Hemant K Roy; Prabhakar Pradhan; Michael J Goldberg; Joseph Muldoon; Randall E Brand; Charles Sturgis; Thomas Hensing; Daniel Ray; Andrej Bogojevic; Jameel Mohammed; Jeen-Soo Chang; Vadim Backman Journal: Cancer Res Date: 2009-06-23 Impact factor: 12.701